当前位置:首页 > 清远分析 > 正文内容

Ripple Therapeutics宣布与艾伯维公司达成合作和许可选择协议,共同开发下一代青光眼治疗方案

admin10个月前 (09-22)清远分析704

- Collaboration to leverage AbbVie's eye care expertise and Ripple's innovative drug delivery platform to develop next-generation sustained release drug delivery implants for the treatment of glaucoma

TORONTO, ON / ACCESSWIRE / September 17, 2024 / Ripple Therapeutics today announced a collaboration and option-to-license agreement with AbbVie to develop RTC-620, a next generation, fully biodegradable, sustained release drug delivery intracameral implant with repeat dosing capabilities to reduce intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). This collaboration leverages AbbVie's expertise in eye care and Ripple's innovative drug delivery platform.

Ripple's patented technology platform is based on a discovery that drugs can be engineered into controlled release pharmaceuticals without the use of polymers or excipients. These proprietary prodrugs undergo surface erosion to give zero order release kinetics and are highly customizable to tailor both drug dose and duration. Because there are no polymers or excipients, once the drug is gone, the implant is gone with no pro-inflammatory degradation products, which supports repeat dosing.

"We're pleased to partner with AbbVie, a worldwide leader in ophthalmic therapeutics," said Tom Reeves, President and Chief Executive Officer, Ripple Therapeutics. "By combining our drug delivery platform with AbbVie's research, clinical, regulatory and commercial capabilities, we hope to deliver a meaningful impact on the lives of people living with glaucoma."

Millions of people are living with glaucoma, one of the leading causes of vision loss. New treatment options are needed to help patients challenged with topical drops or who are at risk for vision loss and looking for alternative treatment options.

"At AbbVie, we strive to find innovative solutions to build our portfolio of vision-preserving therapies," said Michael Robinson, M.D., Vice President and Therapeutic Area Head, Ophthalmology, AbbVie. "We are excited to partner with Ripple to further advance the development of RTC-620."

Under terms of the agreement, Ripple will lead preclinical development of RTC-620. Upon exercise of the option, AbbVie will lead the clinical and commercialization activities. Ripple will receive an upfront payment of $21.8 million from AbbVie and is eligible to receive up to $290 million in aggregate option fees and milestones, as well as tiered royalties on net sales.

About Ripple Therapeutics

Ripple Therapeutics Corporation is a privately held clinical stage company focused on improving ophthalmic therapeutics with controllable sustained delivery implants without the use of polymers or excipients. Our novel therapeutics provide better outcomes for patients, easier management of care for physicians and lower cost for payors.

Piper Sandler acted as the exclusive financial advisor to Ripple.

For further information:

Media: Julie Fotheringham, [email protected], 416-951-7988

SOURCE: Ripple Therapeutics

海量资讯、精准解读,尽在新浪财经APP

扫描二维码推送至手机访问。

版权声明:本文由清远中大创新发布,如需转载请注明出处。

本文链接:http://idrdc.com/post/278.html

分享给朋友:

“Ripple Therapeutics宣布与艾伯维公司达成合作和许可选择协议,共同开发下一代青光眼治疗方案” 的相关文章

A股临近2700点 保卫战

A股临近2700点 保卫战

炒股就看金麒麟分析师研报,权威,专业,及时,全面,助您挖掘潜力主题机会!来源:北京商报9月9日,A股的市场行情引发市场极大关注,当日三大股指集体低开,上证综指最终收跌1.06%,报2736.49点,创今年2月6日以来新低。深证成指收跌0.83%,创业板指则尾盘拉升翻红,收涨0.06%。当日,A股多只...

特朗普威胁要将“作弊者”关进监狱,遭到美国选举官员的痛批

特朗普威胁要将“作弊者”关进监狱,遭到美国选举官员的痛批

财联社9月10日讯(编辑 夏军雄)美国前总统、共和党总统候选人特朗普近日再次发表争议言论,他声称若自己赢得大选,将把那些在选举中“作弊”的人关进监狱。美国选举官员当地时间周一谴责了特朗普的言论。特朗普上周六在他的社交媒体平台Truth Social上发布警告,威胁要将那些在2024年大选中“参与不道...

启迪环境研究院:“构建全面创新体制机制,实现产业深度转型升级”系列报道之创新力量篇

启迪环境研究院:“构建全面创新体制机制,实现产业深度转型升级”系列报道之创新力量篇

炒股就看金麒麟分析师研报,权威,专业,及时,全面,助您挖掘潜力主题机会!一、国重技术转化新质生产力赋能产业高质量发展新格局近日,由启迪环境研究院承担技术服务的山西省孝义市餐厨垃圾制备生物质碳源项目开工建设。这是继今年6月份启迪环境研究院完成为期四年的国家重点研发计划“固废资源化”专项课题“城镇湿垃圾...

5.6万股民猝不及防!A股一上市公司高管被留置 股价闪崩、主力资金出逃

5.6万股民猝不及防!A股一上市公司高管被留置 股价闪崩、主力资金出逃

炒股就看金麒麟分析师研报,权威,专业,及时,全面,助您挖掘潜力主题机会!9月12日晚间,广安爱众(600979.SH)发布公告称,收到控股股东四川爱众发展集团有限公司(下称“爱众集团”)告知函,公司董事张久龙已被立案调查并采取留置措施。受此消息影响,广安爱众9月13日股价大跌5.39%,主力资金净流...

事关以旧换新!河南加力支持→

事关以旧换新!河南加力支持→

河南:加力支持!大河财立方记者获悉,9月13日,河南省人民政府办公厅发布《河南省加力支持大规模设备更新和消费品以旧换新实施方案》。到2024年年底,力争完成个人消费者汽车报废和置换更新30万辆左右,家电产品以旧换新超过200万台,推动淘汰报废老旧营运货车、农业机械3000台套左右,新增新能源中重型营...

长期满仓、常年持股超200只!富国基金朱少醒产品净值跌回2019年

长期满仓、常年持股超200只!富国基金朱少醒产品净值跌回2019年

来源公众号:机构之家富国基金朱少醒作为公募基金的常青树,管理公募基金产品18年来以近15%的年化收益而被冠以“公募巴菲特”的称号。然而,近三年来其业绩表现却引来了诸多质疑,不仅持续跑输指数,近段时间更是净值连创新低,跌回2019年的水平。截止2024年9月11日,朱少醒管理的“富国天惠精选成长”的最...

发表评论

访客

◎欢迎参与讨论,请在这里发表您的看法和观点。